326 related articles for article (PubMed ID: 36999962)
21. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
22. Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid.
Lin L; Hwang BJ; Culton DA; Li N; Burette S; Koller BH; Messingham KA; Fairley JA; Lee JJ; Hall RP; An L; Diaz LA; Liu Z
J Invest Dermatol; 2018 May; 138(5):1032-1043. PubMed ID: 29246800
[TBL] [Abstract][Full Text] [Related]
23. Role of BP230 autoantibodies in bullous pemphigoid.
Shih YC; Wang B; Yuan H; Zheng J; Pan M
J Dermatol; 2020 Apr; 47(4):317-326. PubMed ID: 32048350
[TBL] [Abstract][Full Text] [Related]
24. Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.
Cole C; Vinay K; Borradori L; Amber KT
Front Immunol; 2022; 13():912876. PubMed ID: 35874745
[TBL] [Abstract][Full Text] [Related]
25. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.
Messingham KA; Holahan HM; Fairley JA
Immunol Res; 2014 Aug; 59(1-3):273-8. PubMed ID: 24845463
[TBL] [Abstract][Full Text] [Related]
26. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.
Dimson OG; Giudice GJ; Fu CL; Van den Bergh F; Warren SJ; Janson MM; Fairley JA
J Invest Dermatol; 2003 May; 120(5):784-8. PubMed ID: 12713582
[TBL] [Abstract][Full Text] [Related]
27. Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.
Toh WH; Lee HE; Chen CB
Front Med (Lausanne); 2023; 10():1196946. PubMed ID: 37614956
[TBL] [Abstract][Full Text] [Related]
28. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
Ujiie H
J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
[TBL] [Abstract][Full Text] [Related]
29. BP230 IgE autoantibodies in topical-steroid-resistant bullous pemphigoid.
Shih YC; Yuan H; Shen J; Zheng J; Pan M
J Dermatol; 2021 Sep; 48(9):1372-1380. PubMed ID: 34128260
[TBL] [Abstract][Full Text] [Related]
30. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.
Freire PC; Muñoz CH; Stingl G
Br J Dermatol; 2017 Dec; 177(6):1644-1653. PubMed ID: 28868796
[TBL] [Abstract][Full Text] [Related]
31. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-36 cytokines are overexpressed in the skin and sera of patients with bullous pemphigoid.
Maglie R; Mercurio L; Morelli M; Madonna S; Salemme A; Baffa ME; Quintarelli L; Di Zenzo GM; Antiga E; Albanesi C
Exp Dermatol; 2023 Jun; 32(6):915-921. PubMed ID: 36940975
[TBL] [Abstract][Full Text] [Related]
33. Study of cytokine-induced immunity in bullous pemphigoid: recent developments.
Huang R; Hu L; Jiang F
Ann Med; 2023; 55(2):2280991. PubMed ID: 38109924
[TBL] [Abstract][Full Text] [Related]
34. The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease.
Amber KT; Valdebran M; Kridin K; Grando SA
Front Med (Lausanne); 2018; 5():201. PubMed ID: 30042946
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
Vassallo C; Somenzi A; De Amici M; Barruscotti S; Brazzelli V
Dermatol Ther; 2022 Dec; 35(12):e15946. PubMed ID: 36259470
[TBL] [Abstract][Full Text] [Related]
36. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.
Christophoridis S; Büdinger L; Borradori L; Hunziker T; Merk HF; Hertl M
Br J Dermatol; 2000 Aug; 143(2):349-55. PubMed ID: 10951144
[TBL] [Abstract][Full Text] [Related]
37. Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.
Chen HC; Wang CW; Toh WH; Lee HE; Chung WH; Chen CB
Clin Rev Allergy Immunol; 2023 Dec; 65(3):331-353. PubMed ID: 37897588
[TBL] [Abstract][Full Text] [Related]
38. Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180.
Messingham KA; Onoh A; Vanderah EM; Giudice GJ; Fairley JA
Hybridoma (Larchmt); 2012 Apr; 31(2):111-7. PubMed ID: 22509915
[TBL] [Abstract][Full Text] [Related]
39. Elevated levels of interleukin-9 in the serum of bullous pemphigoid: possible association with the pathogenicity of bullous pemphigoid.
Koga H; Teye K; Sugawara A; Tsutsumi M; Ishii N; Nakama T
Front Immunol; 2023; 14():1135002. PubMed ID: 37398641
[TBL] [Abstract][Full Text] [Related]
40. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Fania L; Caldarola G; Müller R; Brandt O; Pellicano R; Feliciani C; Hertl M
Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
